Stockreport

argenx reports third quarter 2019 financial results and provides business update

argenx SE - American Depositary Shares  (ARGX) 
PDF Enrollment on track for Phase 3 ADAPT trial of efgartigimod in gMG patients with topline results expected in 2H20Two efgartigimod trial initiations expected in 4Q1 [Read more]